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Abstract
Background: Deficient serum vitamin D levels have been associated with incidence of tuberculosis (TB), and latent
tuberculosis infection (LTBI). However, to our knowledge, no studies on vitamin D status and tuberculin skin test (TST)
conversion have been published to date. The aim of this study was to estimate the associations of serum
25-hydroxyvitamin D3 (25[OH]D) status with LTBI prevalence and TST conversion in contacts of active TB in Castellon
(Spain).
Methods: The study was designed in two phases: cross-sectional and case-control. From November 2009 to
October 2010, contacts of 42 TB patients (36 pulmonary, and 6 extra-pulmonary) were studied in order to screen
for TB. LTBI and TST conversion cases were defined following TST, clinical, analytic and radiographic examinations.
Serum 25(OH)D levels were measured by electrochemiluminescence immunoassay (ECLIA) on a COBAS
® 410
ROCHE
® analyzer. Logistic regression models were used in the statistical analysis.
Results: The study comprised 202 people with a participation rate of 60.1%. Only 20.3% of the participants had a
sufficient serum 25(OH)D (≥ 30 ng/ml) level. In the cross-sectional phase, 50 participants had LTBI and no association
between LTBI status and serum 25(OH)D was found. After 2 months, 11 out of 93 negative LTBI participants, without
primary prophylaxis, presented TST conversion with initial serum 25(OH)D levels: a:19.4% (7/36): < 20 ng/ml, b:12.5% (4/
32):20-29 ng/ml, and c:0%(0/25) ≥ 30 ng/ml. A sufficient serum 25(OH)D level was a protector against TST conversion a:
Odds Ratio (OR) = 1.00; b: OR = 0.49 (95% confidence interval (CI) 0.07-2.66); and c: OR = 0.10 (95% CI 0.00-0.76), trends
p = 0.019, adjusted for high exposure and sputum acid-fast bacilli positive index cases. The mean of serum level 25(OH)
D in TST conversion cases was lower than controls,17.5 ± 5.6 ng/ml versus 25.9 ± 13.7 ng/ml (p = 0.041).
Conclusions: The results suggest that sufficient serum 25(OH)D levels protect against TST conversion.
Keywords: Tuberculosis, Vitamin D, Latent tuberculosis infection, Tuberculin skin test conversion, Case-control
study
Background
The hypothesis of vitamin D (VitD) deficiency as a risk
factor for tuberculosis (TB) was postulated by Peter
Davies, based on epidemiological studies of immigrants
from India who developed active TB in the United
Kingdom [1]. Low levels of VitD in blood are associated
with TB [2-4], and hypovitaminosis D is frequent in
patients with TB [5] and children with latent tuberculo-
sis infection (LTBI) [6]. In addition, epidemiological stu-
dies of geographic or seasonal variations of TB
incidence [7-11] and differences in the efficacy of the
Micobacterium bovis bacillus Calmette-Guérin (BCG)
vaccine according to latitude, suggest that a reduction of
VitD levels could increase TB risk [12,13]. Furthermore,
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vitamin D receptor genetic polymorphisms support the
VitD hypothesis [15]. However, there are controversies
about the actions of VitD on the infection: Bruce and
coauthors indicated [16] that: “The evidence does not
support a positive or negative role for VitD in host
resistance to infection”, an alternative VitD action has
been proposed [17], other factors apart from VitD could
be important in relation to the seasonality of TB inci-
dence [18-20], and the VitD hypothesis continues to be
questioned [21].
It has been indicated that the hypothesis of VitD defi-
ciency as a risk factor of TB could be tested by in vitro stu-
dies of immune responses or by case-control studies [22].
In studies where the cases are patients with active TB, it is
difficult to differentiate whether low VitD levels are a cause
or a consequence of the disease [23]. The study of LTBI in
relation to VitD levels using a cross-sectional design pre-
sents a similar problem with positive LTBI cases [24,25].
The study of LTBI in contacts of TB patients and potential
tuberculin skin test (TST) conversions could be considered
as an alternative design. To our knowledge, no studies of
VitD status and TST conversion have been published to
date. The objective of our study was therefore to estimate
associations of VitD status with LTBI prevalence and TST
conversion in contacts of TB patients.
Methods
The study was designed in two phases: the first phase was
cross-sectional and the second, a case-control study. The
period of study was from November 2009 to October
2010. The study involved two health departments in the
province of Castellón (Spain), located on the east cost of
the Iberia Peninsula at latitude 39° N. The two depart-
ments have population of 470,000. The mean annual
hours of sunshine was 2689 for the period 1971-2000
according to data from the Ministry for the Environment
http://www.aemet.es/es/elclima. VitD from sun exposure
is considered to be scarce during the autumn and winter.
The median annual rates of pulmonary and extra-pulmon-
ary TB for years 2006-2010, were 13.4 per 100,000 inhabi-
tants and 1.9 per 100,000 inhabitants, respectively, and the
proportion of foreign-born cases was 44.6%. Although
these incidences could be considered low, they are higher
than most other European countries. In the study period,
53 cases of pulmonary TB and 9 cases of extra-pulmonary
TB were reported to the Castellón Public Health Center.
When a case of TB is reported, an epidemiological study
of the case is carried out by the Epidemiology Division,
and contacts of TB patients are invited to a medical exam-
ination that includes clinical, analytic and radiographic
tests in order to control and prevent the disease.
The study had two phases. In phase I, contacts of TB
patients were studied in the Epidemiology Division of the
Public Health Center and the Preventive Medicine
Service of Hospital La Plana (Vila-real). After an exten-
sive interview, a TST with 2 TU (tuberculin units),
equivalent to 5 IU (international units) of PPD (purified
protein derivative RT-23) from the Serologic Institute of
Copenhagen, was performed following the Mantoux
technique. The test was read 72 hours later. A LTBI case
was defined following a positive TST test result and
negative clinical, analytic and radiographic examinations.
The TST evaluation was considered positive in non
BCG-vaccinated participants with an induration of
≥ 5 mm, or BCG-vaccinated participants with an indura-
tion of ≥ 15 mm or the presentation of vesicles [26].
After 7 days, a booster TST was conducted on partici-
pants older than 54 years or BCG-vaccinated with a
negative first TST. Participants with a history of TB or
with history of treatment for LTBI were considered posi-
tive LTBI. Participants with a negative TST were consid-
ered as controls in this phase. The extensive interviews
with participants provided information on the nature of
contacts (household members, family members, friends,
work or study colleagues), and an average number of
hours per day spent in close contact with the TB patient
(high exposure: 6 or more hours/day, medium exposure:
1-5 hours/day, and low exposure: < 1 h/day). A self-
report questionnaire gathered information on the partici-
pants’ clinical history, demographic variables, weight and
height, habits, use of VitD supplements, and other
variables.
The serum level of 25 hydroxyvitamin D3 (25[OH]D)
was measured by electrochemiluminescence immunoassay
(ECLIA) on a COBAS
® 410 ROCHE
® automate analyzer
[27,28] in the Biochemical Laboratory of the Hospital
General of Castellon. Serum 25(OH)D levels from
0-19 ng/ml range were considered as deficient, 20-29 ng/
ml range as insufficient, and ≥ 30 ng/ml range as sufficient
[29,30]. The analysis was performed on the day the TST
was read, and laboratory staff were unaware of the TST
results.
In phase II (case-control study), two months later, a
new TST was performed on the people who tested LTBI
negative in the first study. TST conversion in non BCG-
vaccinated participants was considered as the change
from negative to positive TST with an increase of ≥ 5
mm on the induration, and in BCG-vaccinated partici-
pants an increase of ≥ 10 mm on the induration from the
initial TST, or the presence of vesicles, (26,31-32). New
clinical, analytic and radiographic examinations were car-
ried out to exclude active TB. Cases were the participants
with positive TST conversion, and controls who pre-
sented negative TST results. Three participants received
primary prophylaxis and were excluded from the case-
control study, and all controls were contacts of pulmon-
ary TB patients.
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ticipants and the low specificity of TST, an alternative ana-
lysis was carried out. Participants with high exposure,
sputum AFB-positive index cases and a TST with ≥ 5m m
of induration were defined as LTBI positive. Participants
without this contact and a TST with ≥ 10 mm of indura-
tion were defined as LTBI positive [33] and BCG status
was not considered. The same TST conversion criterion
was used.
Statistical methods
Qualitative variables were compared with Chi2 and Fisher
tests; quantitative variables were compared using the Krus-
kal-Wallis test. Odds ratios (OR) with 95% confidence
intervals (CI) were calculated by logistic regression. In the
models, prevalent LTBI in phase I, and TST conversion in
phase II were taken as dependent variables. Independent
variables were demographic conditions and potential risk
or protective factors. The independent variables associated
with a p < 0.20 with dependent variables were included in
the logistic regression models, to finally obtain those asso-
ciated with a p < 0.05. The statistical programs used were
STATA version 9 and LogXact [34,35].
The study was approved by the Hospital General of Cas-
tellón Ethics Committee, and signed informed consent
was obtained from all the participants or their parents.
Children younger than 6 years of age were not included in
the study.
Results
From October 2009 to November 2010, 62 TB cases were
reported and 42 TB cases were included in the study, 28
cases of pulmonary TB with sputum acid-fast bacilli (AFB)
positive smear and culture positive Mycobacterium tuber-
culosis, 8 cases of pulmonary TB with culture positive
M. tuberculosis and sputum AFB-negative smear, 3 cases
of TB pleurisy with culture negative M. tuberculosis,a n d3
cases of lymph node TB (1 culture positive and 2 culture
negative M. tuberculosis). The study population comprised
202 contacts of TB patients with a participation rate of
60.1% (202/336). The non-participants presented signifi-
cant differences in the study variables, and were younger
than participants, with a lower foreign-born proportion
and less exposure and sputum AFB-positive index cases.
Contacts of active TB patients were household members,
family members, friends, and work or study colleagues. No
active TB was found among the contacts.
Table 1 presents the description of the study population
broken down into Spanish and foreign-born participants.
The foreign-born participants came from Eastern Europe,
the Maghreb, and Latin America. No differences were
observed in relation to age, gender, or serum 25(OH)D
levels. However, the foreign-born participants presented
more sputum AFB-positive index cases, higher exposure,
and a higher proportion of BCG vaccination than Spanish
participants. Only 20.3% of the participants had a suffi-
cient serum 25(OH)D level. All participants with serum 25
(OH)D levels below 30 ng/ml were referred to a primary
care physician with recommendations to take VitD
supplements.
The results of the cross-sectional study are shown in
Table 2. The prevalence of LTBI was 24.8% (50/202), and
associated factors were male gender, exposure, and high
exposure and sputum AFB-positive index cases. Preventive
chemotherapy was indicated for 35 out of 50 participants
with LTBI, after ruling out the disease. Three out of 14
participants with negative TST results, considering high
exposure and sputum AFB-positive index cases, received
primary prophylaxis with isoniazid for a two months per-
iod, after which one person presented TST conversion.
These indications were independent of VitD status. Serum
25(OH)D levels were not associated with the prevalence of
LTBI. However, sufficient 25(OH)D levels was a protector,
although not significant (OR = 0.82 95% CI 0.36-1.87).
The three participants, who received primary prophylaxis,
had low 25(OH)D levels, 13.16, 22.4, and 22.72 ng/ml,
respectively. In the multivariate analysis, LTBI prevalence
was not associated with serum 25(OH)D levels.
In the second phase, the rate of participation was 69.6%
(96/138) of the LTBI negative participants in phase I. Sig-
nificant differences in the study variables were not found
between participants and non-participants, except for the
high proportion of foreign-born (59.5% versus 33.3% p =
0.004) non-participants. Twelve out of 96 participants
(12.5%) presented TST conversion, and their characteris-
tics are shown in Table 3. Seven patients were BCG-vacci-
nated, and all but one had sputum AFB-positive index
case. All participants that presented TST conversion
received preventive chemotherapy with isoniazid. These
three participants with primary prophylaxis of TB were
excluded of case-control study.
In the case-control study, 11 cases with positive TST
conversion and 82 controls with negative TST results
participated. The results of the case-control study are
shown in Table 4. High exposure to TB patient was asso-
ciated with TST conversion (p = 0.014), and high expo-
sure and sputum AFB-positive index cases presented
strong association with TST conversion. The use of VitD
supplements was not associated with TST conversion.
All eleven TST conversion cases and 57 controls (69.5%)
had low 25(OH)D levels, with means of 25(OH)D con-
centrations of 17.5 ± 5.6 ng/ml and 25.9 ± 13.7 ng/ml,
respectively (p = 0.041). Seasonal variations in serum 25
(OH)D levels were observed. A significant tendency (p =
0.034) was observed between TST conversion and 25
(OH)D levels: 0-19 ng/ml, 20-29 ng/ml, and ≥ 30 ng/ml,
with OR of 1.00, 0.60 (95% CI 0.12-2.66), and 0.13 (95%
CI 0.00-0.91), respectively. When logistic regression
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sented a significant inverse association with TST conver-
sion (OR = 0.10 95% CI 0.00-0.76), adjusted for high
exposure and sputum AFB-positive index cases with a
significant tendency (p = 0.019) (see Table 5).
Results of the alternative analysis revealed 10 partici-
pants out of 86 (11.6%) with TST conversion. The distri-
bution of participants’ serum 25(OH)D levels and TST
conversion were 18.2%(6/33): < 20 ng/ml; 14.3% (4/28)
20-29 ng/ml; and 0.0% (0/25) ≥ 30 ng/ml, respectively. A
s i g n i f i c a n tt e n d e n c y( p=0 . 0 3 0 )w a sf o u n db e t w e e n2 5
(OH)D levels and TST conversion with OR of 1.00, OR =
0.58 (95% CI 0.08-3.24) and OR = 0.11 (95% CI 0.00-
0.87), adjusted for high exposure and sputum AFB-posi-
tive index cases. The mean of 25(OH)D was 19.0 ± 2.9
ng/ml in cases versus 26.3 ± 14.0 ng/ml in controls (p =
0.094).
Discussion
The results indicated that a high proportions of contacts
of TB patients had low serum 25(OH)D levels, and sug-
gested that sufficient 25(OH)D levels protect against
TST conversion. In the cross-sectional study, no differ-
ences in 25(OH)D levels were found between negative
and positive LTBI participants.
Some studies have found high prevalence of low serum
VitD levels in various Spanish populations [36-38], but
this is not general [39]. No Spanish studies of VitD in con-
tacts of TB patients have been published. In the interna-
tional research on VitD and TB, Gibney and co-authors
[24] observed that higher VitD levels were associated with
lower probability of LTBI and TB disease in immigrants
from Sub-Saharan Africa in Melbourne, Australia. In
Vietnam, Ho-Pham and co-authors [40], in a matched
case-control study of TB patients and controls, found that
low serum 25(OH)D levels(< 30 ng/ml) was a risk of
tuberculosis in men, but not in women. In Greenland [41],
a case-control study of TB patients and controls reported
that 25(OH)D levels of < 75 nmol/l or > 140 nmol/l were
associated with high risk for active TB. In Pakistan, a
cohort study of household contacts of pulmonary TB
patients found that VitD deficiency was a risk factor for
active TB (Relative risk = 5.1 95% CI 1.2-21.3) [42], and
this is consistent with our case-control study. Coinciding
with phase I of our study, a cross-sectional study [25] of
Mexican immigrants in Canada found no difference in 25
(OH)D levels between positive LTBI cases and controls. In
a cohort study of Greek dialysis patients, the use of VitD
supplements was not associated with incidence of TB [43].
These studies vary in terms of design, geographic location
Table 1 Characteristics of the study population: Spanish and foreign-born participants
Variables Spanish n = 119 (%) Foreign-born n = 83 (%)
Age (Mean ± SD) 39.9 ± 14.3 32.9 ± 19.9
Male (%) 66 (55.5) 46 (55.4)
25 (OH)Vitamin D3 ng/ml (Mean ± SD) 23.8 ± 13.8 23.68 ± 12.9
Vitamin 25 (OH)D3 ng/ml (Mean ± SD) Oct-March period 19.5 ± 7.8 16.58 ± 7.41
Vitamin 25 (OH)D3 ng/ml (Mean ± SD) Apr-Sept period 25.7 ± 15.5 28.86 ± 13.6
25 (OH)VitaminD3 levels
0-19 ng/ml 55 (46.2) 34(41.0)
20-29 ng/ml 38 (31.9) 34 (41.0)
≥ 30 ng/ml 26 (21.8) 15 (18.0)
Exposure to TB patient
High 35 (29.4) 29(34.9)
Medium 51 (42.9) 44 (53.0)
Low 33 (27.7) 10 (12.1)
High exposure and sputum AFB-positive index cases 19 (15.9) 21 (25.3)
BCG vaccination 36 (30.3) 62 (74.7)
Tuberculosis types
Pulmonary TB sputum positive AFB smear 81(68.1) 74 (89.9)
Pulmonary TB sputum positive culture M. tuberculosis 28 (23.5) 3 (3.6)
Pleurisy 7 (5.9) 2 (2.4)
Lymph node 3 (2.5) 4 (4.8)
Foreign-born population
Eastern Europe 41 (49.4)
Maghreb 13 (15.7)
Latin America 29 (34.9)
SD = Standard deviation. BCG = bacilli Calmette-Guerin. AFB = Acid Fast Bacilli. TB = Tuberculosis
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gender differences, the use of VitD supplements, and the
effects of serum VitD levels.
The antimicrobial effects of VitD have motivated
intense research [44]. In relation to M. tuberculosis,
metabolites of VitD, calcitriol and the induced peptides,
cathelicidin and defensina beta 4, have an important
effect in eliminating the bacilli, including enhancement
of macrophage phagocytosis, activation of monocytes,
cytokines modulation, limitation of intracellular growth
Table 2 Prevalence of latent tuberculosis infection (LTBI) in the study population following the cross-sectional study
Variables Cases Controls OR 95% CI P value
n = 50 (%) n = 152 (%)
Age (years) (Mean ± SD) 38.0 ± 16.9 34.8 ± 14.3 1.02 (0.99-1.04) 0.151
Male 35(70) 77 (50.7) 2.27 (1.15-4.50) 0.019
Foreign-born 22 (44) 61 (40.1) 1.17 (0.61-2.24) 0.630
BCG vaccinated 24 (48) 74 (48.7) 0.97 (0.51-1.84) 0.933
Use vitamin D supplements
1 6 (13.6) 27 (18.0) 0.72 (0.28-1.87) 0.500
Ever smoking
2 20 (46.5) 54 (38.3) 1.40 (0.70-2.79) 0.337
BMI
3(Mean ± SD) 25.7 ± 4.7 25.6 ± 6.3 1.03 (0.97-1.11) 0.315
Sputum AFB-positive index cases 43 (86) 112 (73.7) 2.19 (0.91-5.27) 0.079
Exposure to TB patient
High 28 (52) 36 (23.7) 7.58 (2.42-23.74) 0.001
Medium 18 (40) 77 (50.6) 2.28 (0.72-7.02) 0.160
Low 4 (8) 39 (25.7) 1.00
Trend 0.000
High exposure and sputum AFB-positive index cases 23(46) 17 (11.2) 6.76 (3.19-14.33) 0.000
Study period Apr-Sept 32 (64) 98 (64.5) 0.98 (0.50-1.91) 0.952
25 (OH)Vitamin D3 ng/ml (Mean ± SD) 22.9 ± 11.0 24.0 ± 14.1 0.875
4
25 (OH)Vitamin D3 ng/ml(Mean ± SD) Oct-March period 17.9 ± 7.0 18.2 ± 8.0 0.800
4
25 (OH)Vitamin D3 ng/ml(Mean ± SD) Apr-Sept period 25.7 ± 11.9 27.2 ± 15.7 0.957
4
25(OH) Vitamin D3 ≥ 30 ng/ml 9 (18) 32 (21.1) 0.82 (0.36-1.87) 0.642
25 (OH)Vitamin D3 levels
0-19 ng/ml 22 (44) 67 (44.1) 1.00
20-29 ng/ml 19 (38) 53 (34.9) 1.09 (0.54-2.22)
30 ≥ ng/ml 9 (18) 32 (21.1) 0.86 (0.35-2.07)
Trend 0.812
Comparison of positive LTBI cases and controls. Odds ratios (OR) and 95% confidence interval (CI).
(1) Information on 194 participants. (2) Information on184 participants. (3) Information on 174 participants. (4) Kruskal-Wallis test. SD = Standard deviation. BMI =
Body mass index. AFB = Acid fast bacilli TB = tuberculosis.
Table 3 Characteristic of participants with tuberculin skin test (TST) conversion
N
°
Age Gender Foreign-
born
Sputum AFB-positive index
cases
Exposure to TB
patient
BCG
vaccine
Primary
prophylaxis
TST
1ª
TST
2ª
1 6 Female No Yes High No Yes 0 16
2 21 Female Yes Yes High No No 0 12
3 22 Male Yes Yes Medium Yes No 2 12
4 27 Male No Yes High No No 2 9
5 34 Male Yes Yes High Yes No 10 28
6 37 Male No Yes High No No 0 30
7 38 Male No Yes Medium No No 1 8
8 42 Female Yes Yes High Yes No 0 20
9 46 Male No Yes Medium Yes No 9 16
1
10 55 Male No Yes Medium Yes No 9 19
11 56 Female Yes No
2 Medium No No 4 13
12 57 Female No Yes Medium No No 0 7
(1) Presence of vesicles. (2) Contact with culture positive pulmonary TB patient.
AFB = Acid Fast Bacilli; BCG = Bacilli Calmette-Guerin; TST = Tuberculin Skin Test TB = Tuberculosis
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in pulmonary cavitation [45-48]. In addition, the vitamin
D receptor gene polymorphism plays a key role in sus-
ceptibility to TB [49].
The strengths of our study include the following: its
design is prospective, it studied the contacts of recent
diagnosed TB patients with actual exposure to M. tuber-
culosis, seasonal sunlight variations occurred during the
study, multivariate analysis was applied to control poten-
tial confusion factors and risk of exposure, and a valid
technique was used to determine 25(OH)D levels [50].
The study has some limitations, however. The size of the
study in relation to TST conversion is small. Some
potential confusion factors were studied but unknown
factors could have been present. The measure of VitD
status estimated 25-hydroxyvitamin D3,9 0 %o fV i t Dc i r -
culating in blood, and not vitamin D2, and the technique
has some discordant sensitivity at range limits when it is
compared with radioimmunoassay [51]. There is no gold
standard for the diagnosis of LTBI and the presence of
live M. tuberculosis in LTBI or TST conversion patients
is unknown [52]. The TST has low specificity with the
Table 4 Incidence of tuberculin skin tests (TST) conversion following the case-control study
Variables Cases Controls OR 95% CI P value
N = 11(%) N = 82 (%)
Age (years) (Mean ± SD) 39.6 ± 13.1 34.7 ± 14.5 1.02 (0.98-1.07) 0.299
Male 8 (72.7) 41 (50.0) 2.07 (0.66-10.72) 0.168
Foreign-born 5 (45.5) 26 (31.7) 1.79 (0.50-6.42) 0.363
BCG vaccinated 5 (45.5) 40 (48.8) 0.88 (0.25-3.10) 0.886
Use vitamin D supplements 3 (27.3) 20 (24.7)
1 1.14 (0.28-4.73) 0.853
Ever smoking 6 (54.5) 30 (38.5)
2 1.96 (0.55-6.98) 0.299
BMI(Mean ± SD)
3 25.4 ± 4.6 26.0 ± 6.4 0.98 (0.88-1.10) 0.749
Contact sputum AFB-positive index cases 10 (90.9) 65 (79.3) 2.62 (0.31-21.87) 0.375
Exposure to TB patient
High 5 (45.5) 14 (17.1) 9.16 (1.14-∞) 0.035
Medium 6 (54.5) 47 (57.3) 3.51 (0.49-∞) 0.248
Low 0 (0.0) 21 (25.6) 1.00
Trend 0.014
High exposure and sputum AFB positive index cases 5 (45.5) 6 (7.3) 10.56(2.48-44.95) 0.001
Study period Apr-Sept 6 (54.5%) 61 (74.4) 0.41 (0.11-1.50) 0.178
25 (OH)Vitamin D3 (ng/ml) (Mean ± SD) 17.5 ± 5.6 25.9 ± 13.7 0.041
4
25 (OH) Vitamin D3 ng/ml (Mean ± SD) Oct-March period 15.3 ± 7.4 20.0 ± 9.3 0.242
4
25 (OH) Vitamin D3 ng/ml (Mean ± SD) Apr-Sept period 19.4 ± 2.9 27.9 ± 14.4 0.144
4
25 (OH) Vitamin D3 ≥ 30 ng/ml 0 (0) 25 (30.5) 0.15 (0.00-1.00) 0.050
5
25 (OH) Vitamin D3 levels
0-19 ng/ml 7 (63.6) 29 (35.4) 1.00
20-29 ng/ml 4 (36.4) 28 (34.1) 0.60 (0.12-2.66) 0.660
≥ 30 ng/ml 0 (0.0) 25 (30.5) 0.13 (0.00-0.91) 0.038
Trend 0.034
Comparison of TST conversion cases and controls. Odds ratios (OR) and 95% confidence interval (CI).
(1) Information on 81 controls. (2) Information on 78 controls. (3) Information on 10 cases and 75 controls.(4) Kruskal-Wallis test. (5) Fisher test p = 0.033. SD =
Standard Deviation. BCG = Bacilli Calmette-Guérin. BMI = Body Mass Index AFB = Acid Fast Bacilli. TB = Tuberculosis
Table 5 Risk and protective factors for tuberculin skin test conversion by logistic regression following the case-control
study
Variables OR 95% CI P value
25 (OH)Vitamin D3 levels
0-19 ng/ml 1.00
20-29 ng/ml 0.49 (0.07-2.59) 0.563
≥ 30 ng/ml 0.10 (0.00-0.76) 0.024
Trend 0.019
High exposure TB and sputum AFB positive index cases 14.19 (2.15-120.64) 0.004
Odds ratios (OR) and 95% confidence interval (CI).
AFB = Acid Fast Bacilli. TB = Tuberculosis
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false-positive results are Non-tuberculous Mycobacteria
(NTMB) and BCG vaccination. In Spain, the frequency of
NTMB is considered low, but the proportion of BCG-
vaccinated people over the age of 40 is high, and inter-
feron-g release assays (IGRAS) tests were not used [54].
A booster TST was performed to deal with this issue. In
addition, the incidence of TST conversion was in the
range of results from several other studies of TB contacts
in Spain, 7.8%-12.5% [55,56]. In the cross-sectional study,
the participants presented significant differences from
the non-participants, which is a limitation. However, the
selection bias could be reduced, considering that partici-
pation might not be associated with VitD status. In the
case-control study, only the foreign-born proportion of
non-participants was significantly different. In addition,
the participation rate in the case-control study was
higher than the rates published in other studies in Spain,
range 21.1%-63.3% [55]. Finally, no polymorphism study
of VitD was carried out.
TB patients frequently have lower VitD levels than the
general population [57] and research is still studying the
effect of VitD on the course of the TB disease. In a recent
clinical trial [48], the administration of VitD decreased the
time of sputum culture conversion in pulmonary TB
patients, but the decrease was only significant in patients
with the group tt genotype of the TaqI vitamin D receptor
polymorphism. In contrast, in another clinical trial [58]
the administration of VitD did not improve clinical symp-
toms of TB patients. Our study indicates that it could be
useful to determine 25(OH)D status in contacts of TB
patients as a risk factor for TST conversion. If low 25(OH)
D levels are found, recommendations to take Vit D sup-
plements are pertinent in order to achieve sufficient 25
(OH) D levels. However, only a clinical trial could deter-
mine the therapeutic effects of VitD in contacts of TB
patients [59].
Conclusion
The results of the study suggest that sufficient 25(OH)D
levels protect against TST conversion and support the
hypothesis that deficient VitD status is a TB risk factor.
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